Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 101–200 of 673
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Targeted genes and interacting proteins of hypoxia inducible factor-1.
Liu, W., Shen, S. M., Zhao, X., & Chen, G. Q. (2012) · Europe PMC (PubMed Central) · Cited by 249
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
HIFs and tumors—causes and consequences
Höpfl, G., Ogunshola, O., & Gassmann, M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00538.2003 · Cited by 185
“As such, the molecular chaperone Hsp90 has been identified as a novel VHL- and oxygen-independent regulator of the HIF-1 protein stability (35, 110, 133).”
BackgroundKoh, M. Y., Darnay, B. G., & Powis, G. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00773-08 · Cited by 182
Fu, B., Xue, J., Li, Z., Shi, X., Jiang, B.-H., & Fang, J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0526 · Cited by 181
Sawai, A., Chandarlapaty, S., Greulich, H., Gonen, M., Ye, Q., Arteaga, C. L., Sellers, W., Rosen, N., & Solit, D. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1570 · Cited by 179
Bisht, K. S., Bradbury, C. M., Mattson, D., Kaushal, A., Sowers, A. L., Markovina, S. S., Ortiz, K. L., Sieck, L., Isaacs, J. S., Brechbiel, M. W., et al. (2003) · PubMed · Cited by 178
Self-citationAntioxidant enzymes as redox-based biomarkers: a brief review
Yang, H.-Y., & Lee, T.-H. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.4.274 · Cited by 176
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., De Smaele, E., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 174
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Altered cancer metabolism in mechanisms of immunotherapy resistance
Ramapriyan, R., Caetano, M. S., Barsoumian, H. B., Mafra, A. C. P., Zambalde, E. P., Menon, H., Tsouko, E., Welsh, J. W., & Cortez, M. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.004 · Cited by 170
“HIF-1α also promotes shedding of NKG2D ligands, which results in immune escape from natural killer (NK) cells (Barsoum et al., 2011).”
BackgroundInfluentialRissanen, E., Tranberg, H. K., Sollid, J., Nilsson, G. E., & Nikinmaa, M. (2006) · Journal of Experimental Biology · doi:10.1242/jeb.02103 · Cited by 169
“Cold induces heat shock proteins In mammalian cells, Hsp90–Hsp70 complex binds HIF-1 protein and in that way protects HIF-1 against oxygenindependent proteosomal degradation in both normoxia and hypoxia (Isaacs et al., 2002; Katschinski et al., 2004; Zhou et al., 2004).”
BackgroundPark, S.-K., Dadak, A. M., Haase, V. H., Fontana, L., Giaccia, A. J., & Johnson, R. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4959-4971.2003 · Cited by 169
“The molecular chaperone HSP90 has been implicated as a key component in protecting HIF-1 from VHL-independent ubiquitination and protein degradation in VHL-deficient renal cell carcinoma (RCC) lines ( 17 ).”
BackgroundMaltepe, E., Krampitz, G. W., Okazaki, K. M., Red-Horse, K., Mak, W., Simon, M. C., & Fisher, S. J. (2005) · Development · doi:10.1242/dev.01923 · Cited by 169
“Comparable levels of heat shock protein 90β (HSP90β), which also stabilizes HIF1α in a pVHL- and hypoxia-independent fashion (Isaacs et al., 2002; Katschinski et al., 2002), were expressed in the nuclear compartments of both undifferentiated and differentiated TS cells (Fig.”
BackgroundMcCarty, M. F. (2004) · Integrative Cancer Therapies · doi:10.1177/1534735404270757 · Cited by 169
Baird, N. A., Turnbull, D. W., & Johnson, E. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608013200 · Cited by 168
MEK Guards Proteome Stability and Inhibits Tumor-Suppressive Amyloidogenesis via HSF1
Tang, Z., Dai, S., He, Y., Doty, R. A., Shultz, L. D., Sampson, S. B., & Dai, C. (2015) · Cell · doi:10.1016/j.cell.2015.01.028 · Cited by 168
“Although the mechanisms whereby MEK regulates these key players in oncogenesis are likely multifaceted, accumulating evidence has implicated HSPs in modulating their stabilities (Isaacs et al., 2002; Müller et al., 2004).”
Overexpression of hypoxia-inducible factor and metabolic pathways: possible targets of cancer
Singh, D., Arora, R., Kaur, P., Singh, B., Mannan, R., & Arora, S. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0190-2 · Cited by 166
“Geldanamycin, an HSP90 inhibitor enhances HIF-1α degradation even in cells lacking pVHL [54].”
BackgroundInhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 166
Evolutionary Conserved Regulation of HIF-1β by NF-κB
van Uden, P., Kenneth, N. S., Webster, R., Müller, H. A., Mudie, S., & Rocha, S. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001285 · Cited by 163
Choi, Y. K., Kim, C.-K., Lee, H., Jeoung, D., Ha, K.-S., Kwon, Y.-G., Kim, K.-W., & Kim, Y.-M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131284 · Cited by 161
HIF1α Protein Stability Is Increased by Acetylation at Lysine 709
Geng, H., Liu, Q., Xue, C., David, L. L., Beer, T. M., Thomas, G. V., Dai, M.-S., & Qian, D. Z. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400697 · Cited by 157
“HSP90 is a key cellular chaperone and is positively associated with HIF1 proteins in both normoxia and hypoxia (6).”
BackgroundNew anticancer strategies targeting HIF-1
Yeo, E.-J., Chun, Y.-S., & Park, J.-W. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.040 · Cited by 158
The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
Luo, D., Wang, Z., Wu, J., Jiang, C., & Wu, J. (2014) · BioMed Research International · doi:10.1155/2014/409272 · Cited by 157
Hsp90: an emerging target for breast cancer therapy
Beliakoff, J., & Whitesell, L. J. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000136876.11928.be · Cited by 175
Linehan, W. M., Pinto, P. A., Srinivasan, R., Merino, M. J., Choyke, P. L., Choyke, L. T., Coleman, J., Toro, J. R., Glenn, G. M., Vocke, C. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1870 · Cited by 164
Self-citationLee, J., Jo, D., Park, D., Chung, H. Y., & Mattson, M. P. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007757 · Cited by 161
“The Streptomyces hygroscopicus metabolite geldanamycin binds to the ATP/ADP binding pocket of Hsp90, resulting in inhibition of HIF-1 activation by promoting pVHL-independent proteasomal degradation of HIF-1a protein (Isaacs et al., 2002).”
BackgroundHIF-1: master and commander of the hypoxic world
Mazure, N. M., Brahimi-Horn, M. C., Berta, M., Benizri, E. I., Bilton, R. L., Dayan, F., Ginouvès, A., Berra, E., & Pouysségur, J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.022 · Cited by 181
Shao, R., Zhang, F.-P., Tian, F., Anders Friberg, P., Wang, X., Sjöland, H., & Billig, H. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.05.079 · Cited by 149
Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia
Bartoszewska, S., & Collawn, J. F. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00212-1 · Cited by 146
Yuan, H., Li, X.-Z., Pitera, J. E., Long, D. A., & Woolf, A. S. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63586-9 · Cited by 159
Liu, Y. V., Hubbi, M. E., Pan, F., McDonald, K. R., Mansharamani, M., Cole, R. N., Liu, J. O., & Semenza, G. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705015200 · Cited by 148
Hypoxia: a Double-Edged Sword in Cancer Therapy
Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1245317 · Cited by 147
“The geldanamycin, which can inhibit heat-shock protein 90 (HSP-90), leads to the degradation of HIF-1 protein by proteasome (81, 82).”
BackgroundStructural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin
Oh, S. H., Woo, J. K., Yazici, Y. D., Myers, J. N., Kim, W.-Y., Jin, Q., Hong, S., Park, H., Suh, Y., Kim, K.-W., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm007 · Cited by 153
Ronnen, E. A., Kondagunta, G. V., Ishill, N. M., Sweeney, S. M., DeLuca, J., Schwartz, L. H., Bacik, J., & Motzer, R. J. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9208-z · Cited by 147
Hypoxia‐inducible factor 1 and cancer pathogenesis
Semenza, G. L. (2008) · IUBMB Life · doi:10.1002/iub.93 · Cited by 144
“HSP90 inhibitors, such as geldanamycin and 17-allylaminogeldanamycin (17-AAG), block the binding of HSP90 to HIF-1a (53).”
BackgroundAntiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin
Kaur, G., Belotti, D., Burger, A. M., Fisher-Nielson, K., Borsotti, P., Riccardi, E., Thillainathan, J., Hollingshead, M. G., Sausville, E. A., & Giavazzi, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0795 · Cited by 152
Vadlapatla, R. K., Vadlapudi, A. D., & Mitra, A. K. (2013) · Current Drug Targets · doi:10.2174/13894501113149990015 · Cited by 157
Interaction of the PAS B Domain with HSP90 Accelerates Hypoxia-Inducible Factor-1α Stabilization
Katschinski, D., Le, L., Schindler, S., Thomas, T., Voss, A., & Wenger, R. (2004) · Cellular Physiology and Biochemistry · doi:10.1159/000080345 · Cited by 142
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Rapisarda, A., & Melillo, G. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.002 · Cited by 141
(Aryloxyacetylamino)benzoic Acid Analogues: A New Class of Hypoxia-Inducible Factor-1 Inhibitors
Lee, K., Lee, J. H., Boovanahalli, S. K., Jin, Y., Lee, M., Jin, X., Kim, J. H., Hong, Y.-S., & Lee, J. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0610292 · Cited by 137
Sunkari, V. G., Lind, F., Botusan, I. R., Kashif, A., Liu, Z., Ylä‐Herttuala, S., Brismar, K., Velazquez, O., & Catrina, S. (2015) · Wound Repair and Regeneration · doi:10.1111/wrr.12253 · Cited by 138
Rice, J. W., Veal, J. M., Fadden, R. P., Barabasz, A. F., Partridge, J. M., Barta, T. E., Dubois, L. G., Huang, K. H., Mabbett, S. R., Silinski, M. A. R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24047 · Cited by 137
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
Neckers, L., & Neckers, K. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.137 · Cited by 137
Self-citationHypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Chen, S., & Sang, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25283 · Cited by 145
“…fully understood, efforts to dissect the molecular mechanisms underlying the repressive effects of drugs on HIF-1 indicate the involvement of the molecular chaperone heat shock protein 90 kD (Hsp90) [Isaacs et al., 2002] and heat shock protein 70 kD (Hsp70) [Kong et al., 2006; Luo et al., 2010].”
InfluentialTumor–Microenvironment Interactions: Dangerous Liaisons
Witz, I. P. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00007-9 · Cited by 147
Spotlight on 17‐ AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
Talaei, S., Mellatyar, H., Asadi, A., Akbarzadeh, A., Sheervalilou, R., & Zarghami, N. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13486 · Cited by 142
“…Cell mortality and senescence (Forsythe, Jarvis, Turner, Elmore, & Holt, 2001; Villa et al., 2003) Prostate HIF- 1α Hypoxia- induced angiogenesis (Isaacs et al., 2002; Mabjeesh et al., 2002; Minet et al., 1999) Breast Mutant p53 Mutant form of cell cycle checkpoint protein (Whitesell, Sutphin,…”
BackgroundPalayoor, S. T., Mitchell, J. B., Cerna, D., DeGraff, W., John‐Aryankalayil, M., & Coleman, C. N. (2008) · International Journal of Cancer · doi:10.1002/ijc.23807 · Cited by 132
Genetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruïne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 146
Zhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 126
Linehan, W. M., & Zbar, B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.006 · Cited by 129
COMMD1 disrupts HIF-1α/β dimerization and inhibits human tumor cell invasion
van de Sluis, B., Mao, X., Zhai, Y., Groot, A. J., Vermeulen, J. F., van der Wall, E., van Diest, P. J., Hofker, M. H., Wijmenga, C., Klomp, L. W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40583 · Cited by 126
The potential role of HIF on tumour progression and dissemination
Unwith, S., Zhao, H., Hennah, L., & Ma, D. (2014) · International Journal of Cancer · doi:10.1002/ijc.28889 · Cited by 134
Cathepsin B Regulates the Intrinsic Angiogenic Threshold of Endothelial Cells
Im, E., Venkatakrishnan, A., & Kazlauskas, A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-11-1029 · Cited by 124
“HIF-1α can control VEGF in hypoxia-independent settings as well (Isaacs et al., 2002).”
BackgroundInfluentialHypoxia Inducible Factor-1: Its Potential Role In Cerebral Ischemia
Singh, N., Sharma, G., Mishra, V., & Raghubir, R. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9803-9 · Cited by 136
“The co-immunoprecipitation studies of HIF-1a and pVHL in presence of proteosome inhibitors show a physical interaction between them.”
BackgroundInfluentialHypoxia-inducible factor 1 (HIF-1) in cancer
Quintero, M., Mackenzie, N., & Brennan, P. A. (2004) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.03.008 · Cited by 139
“These include the agents 17-AAG, which induces HIF-1a degradation acting via heat shock protein (HSP 90).(32) Another agent, 2-methoxyoestradiol (2ME2)(33) has also been shown to reduce HIF-1a levels by disrupting microtubule polymerisation.”
BackgroundHIF at the crossroads between ischemia and carcinogenesis
Paul, S. A. M., Simons, J. W., & Mabjeesh, N. J. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10479 · Cited by 121
“More recent discoveries have been added to support that Hsp90 chaperone activity is necessary for HIF-1 transcriptional activation and HIF-1a nuclear accumulation induced by hypoxia or heat (Suzuki et al., 2001; Isaacs et al., 2002; Katschinski et al., 2002; Mabjeesh et al., 2002).”
BackgroundDevelopment of novel therapeutic strategies that target HIF-1
Semenza, G. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.267 · Cited by 120
Chen, S., Yin, C., Lao, T., Liang, D., He, D., Wang, C., & Sang, N. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1055426 · Cited by 119
Treatment of kidney cancer: Insights Provided by the VHL Tumor‐Suppressor Protein
Kaelin, W. G. (2009) · Cancer · doi:10.1002/cncr.24232 · Cited by 129
Glioblastoma, Cancer Stem Cells and Hypoxia
Bar, E. E. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00460.x · Cited by 137
Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function
Kashyap, D., Sharma, A. K., Tuli, H. S., Sak, K., Garg, V. K., Buttar, H. S., Setzer, W. N., & Sethi, G. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.07.037 · Cited by 130
Real-Time Imaging of HIF-1α Stabilization and Degradation
Moroz, E., Carlin, S., Dyomina, K., Burke, S., Thaler, H. T., Blasberg, R., & Serganova, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005077 · Cited by 118
Hypoxia, drug therapy and toxicity
Lee, K., Roth, R. A., & LaPres, J. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.001 · Cited by 136
Xia, L., Ping, M., Huang, W., Zhang, L., Wang, Y., Zhu, H., Tian, D., Liu, J., Chen, Z., Zhang, Y., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs249 · Cited by 129
“polyubiquitylation and rapid degradation of the HIF-1α protein [8].”
BackgroundTargeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
Mellatyar, H., Talaei, S., Pilehvar‐Soltanahmadi, Y., Barzegar, A., Akbarzadeh, A., Shahabi, A., Barekati‐Mowahed, M., & Zarghami, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.102 · Cited by 120
Hypoxia inducible factor-1α: Its role in colorectal carcinogenesis and metastasis
Nagaraju, G. P., Bramhachari, P. V., Raghu, G., & El‐Rayes, B. F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.005 · Cited by 128
“dependently of the pVHL pathway in a renal cell carcinoma (RCC) cell line that lacks a functional pVHL [35].”
BackgroundXiang, L., Gilkes, D. M., Chaturvedi, P., Luo, W., Hu, H., Takano, N., Liang, H., & Semenza, G. L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1102-5 · Cited by 114
“Studies of the first-generation HSP90 inhibitors geldanamycin and 17-allylaminogeldanamycin revealed that displacement of HSP90 from HIF-1α allowed binding of the scaffold protein RACK1, which recruited Elongin C, leading to the ubiquitination and proteasomal degradation of HIF-1α [20], regardless of the O2 concentrat…”
BackgroundRecent agents targeting HIF‐1α for cancer therapy
Hu, Y., Liu, J., & Huang, H. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24390 · Cited by 113
Sanderson, S., Valenti, M. R., Gowan, S. M., Patterson, L., Ahmad, Z., Workman, P., & Eccles, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0439 · Cited by 118
Terzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A. M., Ziche, M., & Melillo, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1075 · Cited by 111
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Martínez‐Sáez, O., Borau, P. G., Alonso‐Gordoa, T., Molina‐Cerrillo, J., & Grande, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.013 · Cited by 116
“Hsp90 inhibitors act throw HIF independent roteasomal degradation impairing transcriptional activity, tumor ell motility and angiogenesis (Isaacs et al., 2002).”
BackgroundHeat shock proteins in mammalian development
Christians, E., Zhou, Q., Renard, J. P. J. P., & Benjamin, I. J. (2003) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2003.09.021 · Cited by 109
Zagzag, D., Nomura, M., Friedlander, D. R., Blanco, C., Gagner, J., Nomura, N., & Newcomb, E. W. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10306 · Cited by 109
“For example, GA blocks tyrosine phosphorylation of FAK and inhibits migration of VEGF-treated endothelial cells (Rousseau et al., 2000).”
BackgroundInfluentialQuality control and fate determination of Hsp90 client proteins
Theodoraki, M. A., & Caplan, A. J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.08.006 · Cited by 127
Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies
Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115036 · Cited by 119
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth
Warfel, N. A., Dolloff, N. G., Dicker, D. T., Malysz, J., & El-Deiry, W. S. (2013) · Cell Cycle · doi:10.4161/cc.26930 · Cited by 108
Kim, K., Choi, J., Kang, I., Kim, K., Jeong, C., & Jeong, J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2012.01030.x · Cited by 117
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., Horvat, R., Jakesz, R., & Birner, P. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9190-3 · Cited by 106
To, K. K. W., & Huang, L. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504342200 · Cited by 106
Nijkamp, M. W., van der Bilt, J. D. W., de Bruijn, M. T., Molenaar, I. Q., Voest, E. E., van Diest, P. J., Kranenburg, O., & Rinkes, I. H. M. B. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a38ef5 · Cited by 114
Chi, N. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.11.033 · Cited by 123
“Further evidence that HSP90 is involved in the regulation of HIF-1a was reported by Isaacs et al. [ 105 ] who showed that disruption of HSP90 function by the HSP90 inhibitor geldanamycin promoted HIF-1a degradation via a novel, oxygen-independent E3 ubiquitin ligase and diminished HIF-1a transcriptional activity.”
BackgroundMilkiewicz, M., Doyle, J. L., Fudalewski, T., Ispanovic, E., Aghasi, M., & Haas, T. L. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.136325 · Cited by 104
“Both HIF-1α and HIF-2α interact with Hsp90 via their bHLH-PAS domains, which facilitates the rapid accumulation of HIF proteins, as well as their DNA-binding and transcriptional activation in normoxic and hypoxic conditions (Minet et al. 1999b; Isaacs et al. 2002; Katschinski et al. 2004).”
BackgroundIdentification of HSP60 as a Primary Target of o-Carboranylphenoxyacetanilide, an HIF-1α Inhibitor
Ban, H. S., Shimizu, K., Minegishi, H., & Nakamura, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104739t · Cited by 106
Chang, D.-J., An, H., Kim, K.-S., Kim, H. H., Jung, J., Lee, J. M., Kim, N., Han, Y. T., Yun, H., Lee, S.-J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301488q · Cited by 112
HIF-1α: a Valid Therapeutic Target for Tumor Therapy
Hong, S., Lee, H., & Kim, K. (2004) · Cancer Research and Treatment · doi:10.4143/crt.2004.36.6.343 · Cited by 125
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L., & Neckers, K. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.277 · Cited by 111
Self-citationHan, J.-Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji251 · Cited by 99
Tafani, M., Pucci, B., Russo, A., Schito, L., Pellegrini, L., Perrone, G. A., Villanova, L., Salvatori, L., Ravenna, L., Petrangeli, E., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00013 · Cited by 99
“However, HIF degradation by ibuprofen was not due to its COX2 inhibition activity (Isaacs et al., 2002).”
BackgroundZhang, D., Li, J., Costa, M., Gao, J., & Huang, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0448 · Cited by 100
“Hsp90 inhibitors, such as geldanamycin, promote HIF-1α ubiqitination and proteasomal-dependent degradation (34).”
BackgroundMicrotubule Disruption Utilizes an NFκB-dependent Pathway to Stabilize HIF-1α Protein
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209804200 · Cited by 99
Self-citationHypoxia/HIF Modulates Immune Responses
Chen, Y., & Gaber, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030260 · Cited by 119
Echeverría, P. C., Matrajt, M., Harb, O. S., Zappia, M. P., Costas, M. A., Roos, D. S., Dubremetz, J., & Angel, S. O. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.031 · Cited by 104
The Ubiquitin-Proteasome System Meets Angiogenesis
Rahimi, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0555 · Cited by 115
Kawanami, D., Mahabeleshwar, G. H., Lin, Z., Atkins, G. B., Hamik, A., Haldar, S. M., Maemura, K., LaManna, J. C., & Jain, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025346 · Cited by 95
VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
Rathmell, W. K., & Chen, S. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.63 · Cited by 107
Koga, F., Kihara, K., & Neckers, L. (2009) · PubMed · Cited by 109
Self-citationIdentification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers
Stany, M. P., Vathipadiekal, V., Ozbun, L. L., Stone, R. L., Mok, S. C., Xue, H., Kagami, T., Wang, Y., McAlpine, J. N., Bowtell, D. D. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021121 · Cited by 107
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.